ciprofloxacin and Hemorrhage studies

Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.

Research Excerpts

Excerpt	Relevance	Reference
"The paper describes the course of two patients with factor V inhibitor, antiphospholipid antibodies and massive bleeding symptoms after treatment with ciprofloxacin."	7.72	[Massive bleeding symptoms in two patients with factor V inhibitor and antiphospholipid antibodies after treatment with ciprofloxacin]. ( Miesbach, W; Peetz, D; Scharrer, I; Voigt, J, 2003)
" Ciprofloxacin prophylaxis appears safe and effective in reducing the incidence of severe BKHC after allogeneic HSCT."	5.37	Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. ( Costa, LJ; Glode, A; Hogan, KR; Kramer, C; Miller, AN; Schaub, C; Stuart, RK, 2011)
" Bleeding is the most common complication observed after prostate biopsy, but the use of aspirin or nonsteroidal anti-inflammatory drugs is not an absolute contraindication to prostate biopsy."	4.89	Complications of prostate biopsy. ( Anastasiadis, A; Antoniewicz, A; Cordeiro, E; De Reijke, T; Dimitriadis, G; Zapała, L, 2013)
"The paper describes the course of two patients with factor V inhibitor, antiphospholipid antibodies and massive bleeding symptoms after treatment with ciprofloxacin."	3.72	[Massive bleeding symptoms in two patients with factor V inhibitor and antiphospholipid antibodies after treatment with ciprofloxacin]. ( Miesbach, W; Peetz, D; Scharrer, I; Voigt, J, 2003)
"Bacterial infections are common in cirrhotic patients with acute variceal bleeding, occurring in 20% within 48 h."	2.50	Role of prophylactic antibiotics in cirrhotic patients with variceal bleeding. ( Lee, YY; Mahadeva, S; Tee, HP, 2014)
" Ciprofloxacin prophylaxis appears safe and effective in reducing the incidence of severe BKHC after allogeneic HSCT."	1.37	Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. ( Costa, LJ; Glode, A; Hogan, KR; Kramer, C; Miller, AN; Schaub, C; Stuart, RK, 2011)

Research

Studies (9)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Acute Rejection at 1 Year

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (22.22)	18.2507
2000's	2 (22.22)	29.6817
2010's	5 (55.56)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Anastasiadis, A	1
Zapała, L	1
Cordeiro, E	1
Antoniewicz, A	1
Dimitriadis, G	1
De Reijke, T	1
Lee, YY	1
Tee, HP	1
Mahadeva, S	1
Valverde, R	1
Arranz, DM	1
Ruiz-Bravo, E	1
Díaz, RM	1
Miller, AN	1
Glode, A	1
Hogan, KR	1
Schaub, C	1
Kramer, C	1
Stuart, RK	1
Costa, LJ	1
Elzir, L	1
Saliba, I	1
Miesbach, W	2
Voigt, J	1
Peetz, D	1
Scharrer, I	1
van Beek, EJ	1
Peters, M	1
ten Cate, JW	1
Vaessen, C	1
Janssen, T	1
Schulman, C	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Ciprofloxacin for Prevention of BK Infection in Renal Transplant Recipients[NCT01789203]	Phase 4	200 participants (Actual)	Interventional	2013-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Number of patients with biopsy-proven acute rejection of the allograft at 1 year, based on Banff classification (NCT01789203)
Timeframe: 12 months

BK Viremia at 1 Year

Intervention	Participants (Count of Participants)
Ciprofloxacin	14
Placebo	7

Proportion of patients developing BK viremia at 1 year (NCT01789203)
Timeframe: 12 months

Clostridium Difficile at 6 Months

Death at 1 Year

First Plasma Viral Loads

Graft Loss at 1 Year

Intervention	Participants (Count of Participants)
Ciprofloxacin	31
Placebo	8

Intervention	Participants (Count of Participants)
Ciprofloxacin	1
Placebo	0

Intervention	Participants (Count of Participants)
Ciprofloxacin	1
Placebo	1

Intervention	copies/mL (Median)
Ciprofloxacin	2514
Placebo	1423

kidney failure within first 1 year of transplant (NCT01789203)
Timeframe: 12 months

Number of Patients Developing BK Infection at 6 Months Post-transplant

Intervention	Participants (Count of Participants)
Ciprofloxacin	14
Placebo	7

Number of patients (followed by proportion) developing BK infection at 6 months post-transplant. BK infection is defined as the presence of a detectable BK viral load in plasma by polymerase chain reaction (PCR), or the presence of BK viral inclusions on kidney biopsy specimens. (NCT01789203)
Timeframe: 6 months

Number of Patients With Bacteremia at 6 Months

Intervention	Participants (Count of Participants)
Ciprofloxacin	25
Placebo	5

Number of patients with bacteremic infection at 6 months. Bacteremia defined by a single positive blood culture that was not thought to be contaminated. (NCT01789203)
Timeframe: 6 months

Number of Patients With Gram Negative Urinary Tract Infections at 6 Months

Intervention	Participants (Count of Participants)
Ciprofloxacin	3
Placebo	2

Number of patients with gram negative urinary tract infections as defined by a midstream urine sample containing 10^4 or more colony-forming units per mL (NCT01789203)
Timeframe: 6 months

Number of Patients With Quinolone-resistant Infection at 6 Months

Intervention	Participants (Count of Participants)
Ciprofloxacin	17
Placebo	14

Number of patients with quinolone-resistant gram negative bacterial infections, among those with a gram-negative infection (NCT01789203)
Timeframe: 6 months

Serious Adverse Events

Intervention	Participants (Count of Participants)
Ciprofloxacin	15
Placebo	7

Serious adverse events collected for up to 4 months (3 months on study drug plus 1 additional month) (NCT01789203)
Timeframe: 4 months

Time to BK Infection

Intervention	Participants (Count of Participants)
Ciprofloxacin	35
Placebo	18

Median time to initial BK viremia episode, days (NCT01789203)
Timeframe: 12 months

Article	Year
[Acral pustules as the key manifestation in the diagnosis of subacute infective endocarditis]. Actas dermo-sifiliograficas, 2010, Volume: 101, Issue:9 Topics: Actinobacillus Infections; Aggregatibacter actinomycetemcomitans; Anti-Bacterial Agents; Aortic Valv	2010
Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:8 Topics: Adult; Aged; Anti-Infective Agents; BK Virus; Ciprofloxacin; Cystitis; Female; Hematologic Neoplasms	2011
Bullous hemorrhagic myringitis. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2013, Volume: 148, Issue:2 Topics: Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Blister; Ciprofloxacin; Dexa	2013
[Massive bleeding symptoms in two patients with factor V inhibitor and antiphospholipid antibodies after treatment with ciprofloxacin]. Medizinische Klinik (Munich, Germany : 1983), 2003, Jun-15, Volume: 98, Issue:6 Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Antibodies, Antiphospholipid; Blood Coagulation Test	2003
Rituximab in the treatment of factor XIII inhibitor possibly caused by Ciprofloxacin. Thrombosis and haemostasis, 2005, Volume: 93, Issue:5 Topics: Anti-Infective Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Autoantibodie	2005
Factor VIII inhibitor associated with ciprofloxacin. Thrombosis and haemostasis, 1993, Apr-01, Volume: 69, Issue:4 Topics: Abscess; Adult; Ciprofloxacin; Factor VIII; Hemophilia A; Hemorrhage; Humans; Postoperative Complica	1993
[Transrectal prostatic biopsy: the role of preventive measures]. Acta urologica Belgica, 1997, Volume: 65, Issue:4 Topics: Adenocarcinoma; Anti-Infective Agents; Antibiotic Prophylaxis; Anticoagulants; Bacterial Infections;	1997

ciprofloxacin and Hemorrhage